Michelle E McClements
Overview
Explore the profile of Michelle E McClements including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
979
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fry L, Major L, Salman A, McDermott L, Yang J, King A, et al.
Commun Biol
. 2025 Feb;
8(1):200.
PMID: 39922978
CRISPR-Cas13 systems have therapeutic promise for the precise correction of point mutations in RNA. Using adenosine deaminase acting on RNA (ADAR) effectors, A-I base conversions can be targeted using guide...
2.
Quinn J, Salman A, Paluch C, Jackson-Wood M, McClements M, Luo J, et al.
Sci Rep
. 2024 Aug;
14(1):20033.
PMID: 39198470
Uveitis is characterised by breakdown of the blood-retinal barrier (BRB), allowing infiltration of immune cells that mediate intraocular inflammation, which can lead to irreversible damage of the neuroretina and the...
3.
Ng B, Kaukonen M, McClements M, Shamsnajafabadi H, MacLaren R, Cehajic-Kapetanovic J
Prog Retin Eye Res
. 2024 Aug;
102:101289.
PMID: 39127142
Conventional gene therapy involving supplementation only treats loss-of-function diseases and is limited by viral packaging sizes, precluding therapy of large genes. The discovery of CRISPR/Cas has led to a paradigm...
4.
McClements M, Abdalla Elsayed M, Major L, de la Camara C, MacLaren R
Mol Diagn Ther
. 2024 Jul;
28(5):575-591.
PMID: 38955952
Gene therapies have emerged as promising treatments in clinical development for various retinal disorders, offering hope to patients with inherited degenerative eye conditions. Several gene therapies have already shown remarkable...
5.
Yusuf I, Burgoyne T, Salman A, McClements M, MacLaren R, Charbel Issa P
Mol Ther
. 2024 Mar;
32(5):1445-1460.
PMID: 38504520
Age-related macular degeneration (AMD) is the most common cause of untreatable blindness in the developed world. Recently, CDHR1 has been identified as the cause of a subset of AMD that...
6.
Salman A, McClements M, MacLaren R
Int J Mol Sci
. 2024 Feb;
25(3).
PMID: 38338978
Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss among the elderly in the developed world. Whilst AMD is a multifactorial disease, the involvement of the complement...
7.
Bellingrath J, McClements M, Fischer M, MacLaren R
Front Mol Neurosci
. 2023 Jun;
16:1092913.
PMID: 37293541
RNA editing holds great promise for the therapeutic correction of pathogenic, single nucleotide variants (SNV) in the human transcriptome since it does not risk creating permanent off-targets edits in the...
8.
Major L, McClements M, MacLaren R
Int J Mol Sci
. 2023 Apr;
24(8).
PMID: 37108761
This review considers research into the treatment of Usher syndrome, a deaf-blindness syndrome inherited in an autosomal recessive manner. Usher syndrome mutations are markedly heterogeneous, involving many different genes, and...
9.
Chandler L, Barnard A, Caddy S, Patricio M, McClements M, Fu H, et al.
Mol Ther Methods Clin Dev
. 2023 Feb;
28:300.
PMID: 36843676
[This corrects the article DOI: 10.1016/j.omtm.2019.05.012.].
10.
Hansen S, McClements M, Corydon T, MacLaren R
Cells
. 2023 Feb;
12(3.
PMID: 36766782
Inherited retinal diseases (IRD) are a clinically and genetically heterogenous group of diseases and a leading cause of blindness in the working-age population. Even though gene augmentation therapies have shown...